# CELLAPEUTICSBIO

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellapeuticsbio

- Industry: Healthcare
- Headquarters: Seongnam, South Korea
- Website: www.cellapeuticsbio.com
- Total disclosed funding: $3.7M
- Latest round: Series A (May 14, 2023)
- Investors on record: 4

## About

Founded in 2020 and based in Seongnam-si, South Korea, CELLAPEUTICSBIO is a cell therapy reprogramming company specializing in cells and antibody combinations used in the development of a treatment for severe intractable nerve damage. In May 2023, CELLAPEUTICSBIO raised KRW 5 billion in series A funding from new investors Medytox Venture Investment and Kiwoom Investment. Returning investor DAYLI Partners also participated in this round.

## Funding rounds

- Series A, May 14, 2023, $3.7M — Kiwoom Investment, DAYLI Partners, Medytox Venture Investment
- Seed, Jun 1, 2020 — Korea Tech Incubator for Startup, Medytox Venture Investment

## Investors

- Korea Tech Incubator for Startup — Seed
- Medytox Venture Investment (https://capitalatlas.ai/funds/medytox-venture-investment) — Seed, Series A
- Kiwoom Investment (https://capitalatlas.ai/funds/kiwoom-investment) — Series A
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series A